The effect of substance P (SP) on thyrotropin (TSH) secretion is controversial. In this study we evaluated the effect of SP on TSH secretion by hemipituitaries of 3-month-old Wistar rats in vitro and its interaction with gastrin-releasing peptide (GRP) at equimolar concentrations (1 µM and 10 µM). TSH release was measured under basal conditions and 30 min after incubation in the absence or presence of SP, GRP or both peptides. Pituitary TSH content was also measured in the pituitary homogenate after incubation. SP at both concentrations caused a significant (P<0.05) increase in TSH secretion compared with all other groups, which was approximately 60% (1 µM) and 85% (10 µM) higher than that of the control group (23.3 ± 3.0 ng/ml). GRP at the lower concentration did not produce a statistically significant change in TSH secretion, whereas at the concentration of 10 µM it produced a 50% reduction in TSH. GRP co-incubated with substance P completely blocked the stimulatory effect of SP at both concentrations. Pituitary TSH content decreased in the SP-treated group compared to controls (0.75 ± 0.03 µg/hemipituitary) at the same proportion as the increase in TSH secretion, and this effect was also blocked when GRP and SP were co-incubated. In conclusion, in an in vitro system, SP increased TSH secretion acting directly at the pituitary level and this effect was blocked by GRP, suggesting that GRP is more potent than SP on TSH secretion, and that this inhibitory effect could be the predominant effect in vivo.
Introduction
Substance P (SP) is a tachykinin peptide with 11 amino acids which is expressed in numerous neural and endocrine tissues (1) . The highest SP concentration is found in rat and primate hypothalamic extracts (2) (3) (4) (5) . A high density of immunoreactive SP is present in the rat and primate hypothalamus in areas involved in the control of anterior pituitary function (2) (3) (4) . In rats, substance Pimmunoreactive neurons have been observed in the arcuate nucleus, the medial preoptic area, and the periventricular zone (2, 3) . SP quantification by radioimmunoassay confirmed the presence of significant amounts of substance P in the paraventricular nucleus (PVN) and also in the median eminence of rats (6) . Furthermore, in the median eminence, SP-like-immunoreactive fibers are present in abundance, and nerve terminals of SP fibers contact the basal lamina of capillaries in the hypophyseal portal circulation (7) . These data support the view that substance P plays a role in the regulation of the anterior pituitary, acting as a hypothalamic neurohormone and reaching the pituitary through the portal circulation (4,7).
However, SP has also been detected by immunocytochemistry within thyrotrophs, lactotrophs and somatotrophs of the rat anterior pituitary (8, 9) as well as within a subset of thyrotrophs in the human pituitary (10) . The presence of preprotachykinin A mRNA in the anterior pituitary gland (11) suggests that SP is synthesized in the gland. Therefore, it is likely that, in addition to hypothalamic SP, pituitary hormone secretion may be regulated by SP produced within the gland in an autocrine/paracrine manner.
In addition, a direct effect of SP is supported by the finding of specific high affinity binding sites for SP in the pituitary gland (12, 13) that have been characterized as type 1 neurokinin receptors, whose endogenous ligand is SP (13) . These receptors, similar to those of hypothalamic hormones, such as TRH (thyrotropin-releasing hormone), stimulate phosphatidylinositol 4,5-biphosphatespecific phospholipase C activity (14) .
SP isolated from hypothalamic extracts has been shown to have several effects on anterior pituitary secretion (1). Substance P injected into the lateral ventricle of female Rhesus monkey increased prolactin and decreased growth hormone concentrations in serum (15) , while in the rat these effects were variable, perhaps depending on the concentration employed (16) (17) (18) (19) (20) . The effect on LH is controversial and depends on the species studied, the route of administration and sex-steroid hormonal status (16) (17) (18) 21) . SP decreased ACTH secretion and stimulated arginine-vasopressin secretion in rats (22) .
The action of SP upon thyrotropin (TSH) secretion is also controversial. While Mitsuma and Nogimori (23) found a decrease in serum TSH and a blockade of TRH-or cold exposure-induced TSH-release when SP was injected intravenously into male rats, Arisawa et al. (24, 25) found no effect in vivo when SP was injected either intravenously or into the third cerebral ventricule, or in vitro when the peptide was added to the medium for dispersed anterior pituitary cells.
We have shown that two bombesin-like peptides, neuromedin B (NB) (26) and gastrin-releasing peptide (GRP) (27) , inhibit TSH secretion. NB content (28, 29) and action (26, 30) at the pituitary gland level are influenced by thyroid status. Hypothyroidism decreases, while thyroid hormone increases pituitary NB and its mRNA content (28, 29) . Also, SP concentration in the anterior pituitary is modified by thyroid status. Thyroidectomy increases, while hyperthyroidism decreases the content of the peptide and its prohormone-encoding mRNA (11, 31, 32) , and the same occurs in the central nervous system of hypo-and hyperthyroid rats (33) . Taken together, these data raise the possibility that bombesin-like peptides and SP interact to modulate TSH secretion. There are some SP analogs that function as SP and GRP or bombesin antagonists in several biological systems (34, 35) . In the present study we tested the effect of SP and its interaction with GRP on TSH secretion in vitro.
Material and Methods

Animals
Three-month-old male Wistar rats (250-280 g) were housed under controlled conditions of temperature (24 ± 1 o C) and light (12 h light starting 7 a.m.). The animals were bred in our animal facilities. 
In vitro experiment
The animals were sacrificed by decapitation. Pituitaries were quickly dissected out, the anterior pituitary was separated from the posterior pituitary, and each anterior hemipituitary was immediately transferred to a tube containing 1.0 ml of 199 medium (Sigma Chemical Co., St. Louis, MO, USA) plus 0.1% bacitracin and 10 mM HEPES (Sigma), pH 7.4, and incubated at 37 o C in a Dubnoff metabolic shaker. In two sets of experiments, the glands were divided into four groups of 10 hemipituitaries each: 1) control, 2) SP, 3) GRP and 4) SP + GRP. Both peptides (purchased from Peninsula Laboratories, Palo Alto, CA, USA) were added to a final concentration of 1 µM or 10 µM. After 30 min of pre-incubation the medium was removed, the hemipituitaries were resuspended in 1 ml of fresh medium and after 30 min an aliquot was collected for measurement of basal TSH. Then, 10 µl of medium alone or the peptide(s) corresponding to each group was added to each tube. After 30 min another aliquot was collected to measure post-stimulus TSH. The values are reported as the difference between stimulated TSH and basal TSH (D TSH). Each hemipituitary was homogenized in phosphate-buffered saline containing 1% bovine serum albumin (Sigma), pH 7.6, for measurement of intrapituitary TSH.
Radioimmunoassay
TSH concentrations in the incubation medium and homogenates were determined by radioimmunoassay using kits supplied by the National Institute of Diabetes, Digestive and Kidney Diseases and are reported in terms of the reference preparation provided (RP2).
Statistical analysis
Data are reported as means ± SEM. Oneway analysis of variance (ANOVA) followed by the Newman-Keuls multiple comparison test was used for data analysis, with the level of significance set at P<0.05.
Results
As expected, there was no difference in basal TSH secretion amongst the groups studied (data not shown). The incubation with 1 µM substance P caused a significant (P<0.05) increase in TSH secretion compared with all other groups studied, causing approximately a 59% higher TSH release than the control group ( Figure 1, panel A) . GRP at the same concentration produced a smaller nonsignificant decrease in TSH secretion, but when co-incubated with substance P, GRP completely blocked the stimulatory effect of substance P (Figure 1, panel A) . Incubation with the peptides at the ten-fold higher concentration (10 µM) produced a greater release of TSH by the pituitaries incubated with SP (87%, P<0.001), while GRP-incubated pitu- * itaries had a 50% lower TSH concentration in the medium (P<0.001). Again, GRP coincubated with SP blocked the stimulatory effect of the peptide (Figure 1, panel B) .
The TSH content in the pituitaries incubated with both peptides at the concentrations of 1 µM and 10 µM was lower in the SP group and inversely proportional to the observed increase in TSH secretion (63% at 1 µM and 85% at 10 µM), an effect which was also inhibited by co-incubation with GRP ( Figure 2, panels A and B) . GRP alone did not affect pituitary TSH concentration at 1 µM, but TSH concentration was 25% higher when GRP was added at 10 µM.
Discussion
We studied the effect of substance P on TSH secretion and its interaction with GRP, a bombesin-like peptide, which we have previously shown to inhibit TSH secretion in vitro at the concentration of 10 µM (27) . In the present study, we also used a 10-times lower GRP concentration. At this concentration GRP did not affect TSH secretion by isolated pituitaries. The concentration of 1 µM substance P was chosen because in initial experiments (data not shown) we showed that 1 µM was the minimum SP concentration able to increase TSH secretion. The other concentrations studied were 1, 10 and 100 nM.
The inhibitory effect of 10 µM GRP on TSH secretion by isolated pituitaries was maintained even when SP was co-incubated at the concentration that caused an 87% higher TSH release into the medium, when SP was incubated alone. Even at the lower molarity, at which GRP did not change TSH secretion and SP-incubated pituitaries presented a 59% higher TSH secretion, this effect was blocked by GRP co-incubation. These data suggest that GRP can function as an SP antagonist in the control of TSH secretion and in this case it is more potent than SP. It is unlikely that this blockade could be due to a summation of opposite effects since at both concentrations studied pituitaries coincubated with both peptides showed lower TSH secretion than the control group. More experiments are needed to elucidate the mechanisms of this antagonism.
There are reports of interaction of SP and bombesin-like peptides, but none was related to TSH secretion. The contractile effect of bombesin on the guinea-pig isolated taenia coli (35) was antagonized by SP antagonists. This observation raised the possibility that bombesin and SP interact with each others receptors (35) . This also may be the case for GRP in view of the structural homology between bombesin and GRP. However, it is also possible that GRP and SP have opposite and independent effects on TSH release, GRP being more potent than SP.
Intraventricular or intravenous administration of SP failed to alter TSH release in male rats, but stimulated TSH secretion in estrogen-primed ovariectomized rats (25) . However, Mitsuma and Nogimori (23) found a suppressive effect of SP injected iv on TSH release in male rats. The discrepancy be- tween the results of those experiments might be related to the different SP doses employed and to the fact that their results were obtained in vivo, while ours were obtained in vitro. Our study establishes that substance P has a direct stimulatory effect at the pituitary level. The fact that Arisawa et al. (18) did not find any effect of SP on pituitary cells cultured overnight might be related to differences in the in vitro systems utilized or to different times of incubation. Vijayan and McCann (16) also did not find any effect of SP on TSH secretion using a methodological approach similar to ours, however, they studied ovariectomized female rats. Therefore, it appears that the sex and sex-hormone status of the animal influence the TSH response to SP. In support of this hypothesis, it has been demonstrated that the distribution of substance P in different pituitary cell populations is sexually dimorphic (36) .
The observed direct effect of exogenous SP on TSH secretion agrees with the presence of SP receptors in the pituitary gland (12) (13) (14) , which, physiologically, might be activated by hypothalamic SP or the locally produced peptide, which has been localized within the thyrotroph by immunocytochemistry (8, 10) .
Several lines of evidence suggest an interplay between SP and NB/GRP in TSH secretion. Both peptides have been shown to be present in the thyrotrophs, and they have opposite effects on TSH secretion, with SP increasing it while NB and GRP decrease it (26, 27, 30) . Their pituitary levels are modified in opposite directions by thyroid hormone. Pituitary SP content decreases, while NB content increases with thyroxine administration (28, 29, 31, 32) and in hypothyroidism the reverse occurs for both peptides (30, 31) . We have shown in the present paper that GRP antagonized the effect of SP on TSH secretion. Therefore, it is tempting to propose that these peptides could play a role as local regulators in the inhibition of TSH secretion caused by thyroid hormones, modulating each others effects.
